NDA 050629 · Pfizer
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride · Injection
Priority reviewLast checked: Nov 19, 2026Latest source record: May 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Dec 23, 1987
Approved uses
2
Original approval plus efficacy supplements
Registered trials
2,822
757 Phase 3, 308 recruiting
FAERS reports
90,406
87,225 serious, 17,155 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1%–20% for cumulative doses ranging from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including...
What it is approved for
From the label in effect May 5, 2026.
Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
Mechanism: The cytotoxic effect of doxorubicin hydrochloride on malignant cells and its toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities of doxorubicin. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin hydrochloride cytocidal activity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 8, 2003 Supplement 14 · Efficacy LetterLabel
- Dec 23, 1987 Original approval · Type 3 - New Dosage Form · priority review
3 products under this application
- DOXORUBICIN HYDROCHLORIDE · DOXORUBICIN HYDROCHLORIDE 200MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- DOXORUBICIN HYDROCHLORIDE · DOXORUBICIN HYDROCHLORIDE 150MG/75ML · INJECTABLE, INJECTION · Discontinued
- DOXORUBICIN HYDROCHLORIDE · DOXORUBICIN HYDROCHLORIDE 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxorubicin" as an intervention, any sponsor and status, largest first.
- Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell LineStatus unknown
Cairo UniversityAcademic, hospital or other
NCT05456022 · 1,000,000 participants (planned) · Start Jul 2022 · Primary completion Dec 2023
Drug: Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT) and 1 more · For: Oral Cancer
Sites: Cairo, Egypt
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia9,348
- off label use9,066
- disease progression6,613
- neutropenia6,563
- drug ineffective5,304
- pyrexia4,149
- anaemia3,892
- thrombocytopenia3,886
- nausea3,232
- death3,157
- product use in unapproved indication3,006
- pneumonia2,941
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 232 |
| 2005 | 407 |
| 2006 | 282 |
| 2007 | 441 |
| 2008 | 437 |
| 2009 | 243 |
| 2010 | 366 |
| 2011 | 958 |
| 2012 | 1,762 |
| 2013 | 3,400 |
| 2014 | 2,964 |
| 2015 | 4,015 |
| 2016 | 3,682 |
| 2017 | 4,635 |
| 2018 | 6,759 |
| 2019 | 5,769 |
| 2020 | 6,572 |
| 2021 | 5,778 |
| 2022 | 8,314 |
| 2023 | 10,057 |
| 2024 | 9,571 |
| 2025 | 8,071 |
| 2026 | 5,691 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
Pautier P, Italiano A, Piperno-Neumann S, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, et al. · Lancet Oncol 2022 · Clinical Trial, Phase III, Multicenter Study
- Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity.
Ozcan M, Guo Z, Valenzuela Ripoll C, et al. · Cell Metab 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
Pervaiz N, Colterjohn N, Farrokhyar F, et al. · Cancer 2008 · Meta-Analysis, Systematic Review
- Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways.
Hiensch AE, Bolam KA, Mijwel S, et al. · Acta Physiol (Oxf) 2020 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.